z-logo
open-access-imgOpen Access
Caspase inhibitors reduce severity of cartilage lesions in experimental osteoarthritis
Author(s) -
D'Lima Darryl,
Hermida Juan,
Hashimoto Sanshiro,
Colwell Clifford,
Lotz Martin
Publication year - 2006
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.21874
Subject(s) - osteoarthritis , medicine , apoptosis , poly adp ribose polymerase , cartilage , caspase 3 , caspase , chondrocyte , immunohistochemistry , caspase 9 , programmed cell death , pathology , pathogenesis , pharmacology , chemistry , enzyme , anatomy , polymerase , biochemistry , alternative medicine
Objective To examine the therapeutic efficacy of caspase inhibitors in experimental osteoarthritis (OA). Methods Experimental OA was induced in rabbits by anterior cruciate ligament transection (ACLT). Rabbits were treated with intraarticular (IA) injections of caspase inhibitors 3 times per week starting 1 week postoperatively. Animals were killed 9 weeks after ACLT, for macroscopic, histologic, and immunohistochemical assessment of the knee joints. Results IA administration of the pan‐caspase inhibitor Z‐VAD‐FMK significantly reduced cartilage degradation, as assessed by macroscopic and microscopic criteria. Untreated knees showed large numbers of chondrocytes with active caspase 3 and the p85 fragment of poly(ADP‐ribose) polymerase (PARP p85) that is generated during apoptosis. The frequency of cells positive for PARP p85 and active caspase 3 was reduced in Z‐VAD‐FMK–treated knees. Inhibitors specific for caspase 3 or caspase 8 showed no significant efficacy. Caspase 1 inhibitor and the combination of caspase 3 and caspase 8 inhibitors reduced OA pathology. Conclusion These results provide direct support for a role of cell death in OA pathogenesis. Caspase inhibitors reduced the severity of cartilage lesions in experimental OA, suggesting that they may have disease‐modifying activity in human OA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here